TORONTO, ONTARIO--(Marketwired - May 15, 2017) - Bradmer Pharmaceuticals Inc. ("Bradmer" or the "Company") BMR today announced its first quarter 2017 financial results.

Financial Results

Amounts in US dollars, unless specified otherwise, and results prepared in accordance with International Financial Reporting Standards ("IFRS").

For the three months ended March 31, 2017, we recorded a net loss of $33,000 or $0.002 per common share based on the weighted average outstanding shares of 19,659,726 during the three month period, compared to a net loss of $52,000 or $0.003 per common share for the quarter ended March 31, 2016 based on the weighted average outstanding shares of 19,659,726.

General and administrative expenses were $28,000 in the three months ended March 31, 2017 compared to $26,000 in the same quarter of the prior year. Major expenses in 2017 consisted of consulting fees of $13,600, legal fees of $6,000, directors' and officers' liability insurance premiums of $2,400 and audit fees of $2,800. In 2016 major expenses consisted of consulting fees of $13,100, transfer agent and regulatory fees of $7,500, directors' and officers' liability insurance premiums of $2,400 and audit fees of $2,200.

The $5,000 foreign exchange loss in the first quarter of 2017 compared with a $26,000 foreign exchange loss in the same quarter of 2016.

Bradmer's operational activities for the three months ended March 31, 2017 were financed by cash on hand. At March 31, 2017, the Company had working capital of $352,000, compared to $382,000 at December 31, 2016. We had available cash of $350,000 (CDN $465,000) as at March 31, 2017, compared to cash of $414,000 (CDN $556,000) as at December 31, 2016. The $64,000 decrease in cash was due to the $33,000 net loss and the $35,000 increase in non-cash working capital, offset by $4,000 of foreign currency adjustments.

As at May 15 and March 31, 2017, the Company had 19,659,726 common shares and options to purchase 1,950,000 common shares outstanding.

Bradmer Pharmaceuticals Inc.

Paul Van Damme
Chief Financial Officer

Additional information about Bradmer, including the MD&A and financial results may be found on SEDAR at www.sedar.com.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Bradmer's common shares have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.

Except for historical information, this news release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

BRADMER PHARMACEUTICALS INC.
Condensed Interim Statements of Financial Position
As at
(All amounts expressed in United States dollars)

			March 31,			December 31
			2017			2016
Assets
Current assets
	Cash		$	349,619		$	413,894
	Amounts receivable			3,710			3,413
	Prepaid expenses			9,254			1,176
Total assets			$	362,583		$	418,483
Liabilities and Shareholders' Equity
Current liabilities
	Accounts payable and accrued liabilities		$	10,330		$	36,759
Shareholders' Equity
	Share capital			1,726,597			1,710,138
	Contributed surplus			1,907,943			1,889,755
	Accumulated other comprehensive income			864,534			895,332
	Deficit			(4,146,821)			(4,113,501)
Total shareholders' equity				352,253			381,724
Total liabilities and shareholders' equity			$	362,583		$	418,483

BRADMER PHARMACEUTICALS INC.
Condensed Interim Statements of Comprehensive Income
For the three months ended March 31
(All amounts expressed in United States dollars)

			2017			2016
Expenses
	General and administrative		$	28,199			26,448
Other Income
	Interest			(27)			(29)
	Foreign exchange loss			5,148			25,676
Loss for the period			$	33,320		$	52,095
Other comprehensive loss				30,798			203,571
Comprehensive loss for the period			$	64,118		$	255,666
Loss per share
Basic and diluted			$	0.002		$	0.003
Weighted average number of shares outstanding				19,659,726			19,659,726

BRADMER PHARMACEUTICALS INC.
Condensed Interim Statements of Changes in Shareholders' Equity
For the three months ended March 31
(All amounts expressed in United States dollars)

		Share capital
		Number of shares		Amount			Contributed surplus		Accumulated Other Comprehensive Income/ (Loss)			Deficit			Total Shareholders' equity
Balance, January 1, 2016		19,659,726		$	1,659,105		$	1,833,363	$	985,568		$	(3,977,951)		$	500,085
Foreign currency translation adjustment		-			111,153			122,827		(203,571)			-			30,409
Loss for the period		-			-			-		-			(52,095)			(52,095)
Balance, March 31, 2016		19,659,726		$	1,770,258		$	1,956,190	$	781,997		$	(4,030,046)		$	478,399
Balance, January 1, 2017		19,659,726		$	1,710,138		$	1,889,755	$	895,332		$	(4,113,501)		$	381,724
Foreign currency translation adjustment		-			16,459			18,188		(30,798)			-			3,849
Loss for the period		-			-			-		-			(33,320)			(33,320)
Balance, March 31, 2017		19,659,726		$	1,726,597		$	1,907,943	$	864,534		$	(4,146,821)		$	352,253

BRADMER PHARMACEUTICALS INC.
Condensed Interim Statements of Cash Flows
For the three months ended March 31
(All amounts expressed in United States dollars)

				2017			2016
Cash flows from operating activities
	Loss for the period			$	(33,320)		$	(52,095)
	Adjustments for:
		Foreign currency translation adjustment			3,754			24,695
					(29,567)			(27,400)
	Change in non-cash operating items
		Amounts receivable			(297)			2,882
		Prepaid expenses			(8,078)			(7,256)
		Accounts payable and accrued expenses			(26,429)			(1,425)
					(64,371)			(33,199)
Effect of exchange rate fluctuations on cash held					96			5,713
Decrease in cash					(64,275)			(27,486)
Cash at beginning of period					413,894			520,758
Cash at end of period				$	349,619		$	493,272